Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torlak Seasonal Trivalent Influenza Vaccine Phase 1 Study
NCT02585700Phase 1Completed
- Sponsor
- Institute Torlak
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza vaccine in influenza, sponsored by Institute Torlak. Primary endpoints: Number of Subjects With Immediate Adverse Events at 30 months and Number and Percentage of Subjects With Solicited Local Reactogenicity at 7 days. Started Nov 2015; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02585700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585700.